Assessment of the Variability in Influenza A(H1N1) Vaccine Effectiveness Estimates Dependent on Outcome and Methodological Approach
نویسندگان
چکیده
BACKGROUND Estimation of Influenza vaccine effectiveness (VE) varies with study design, clinical outcome considered and statistical methodology used. By estimating VE using differing outcomes and statistical methods on the same cohort of individuals the variability in the estimates produced can be better understood. The Pandemic Influenza Primary Care Reporting (PIPeR) cohort of approximately 193,000 individuals was used to estimate pandemic VE in Scotland during season 2009-10. VE results for three outcomes; influenza related consultations, virological confirmed influenza and death were considered. Use of individualised records allowed all models to be adjusted for age, sex, deprivation, risk status relating to chronic illnesses, seasonal vaccination status and a marker of the individual's propensity to consult. For the consultation and death outcomes, VE was calculated by comparing consultation rates in the unvaccinated and vaccinated groups, adjusted for the listed factors, using both Cox and Poisson regression models. For the consultation outcome, the unvaccinated group was split into individuals before vaccination and those never vaccinated to allow for potential differences in the health seeking behaviour of these groups. For the virology outcome estimates were calculated using a generalised additive logistic regression model. All models were adjusted for time. Vaccine effect was demonstrated for the influenza-like illness consultation outcome using the Cox model (VE=49% 95% CI (19%, 67%)) with lower estimates from the model splitting the before and never vaccinated groups (VE=34.2% with 95% CI (-0.5%, 58.9%)). Vaccine effect was also illustrated for overall mortality (VE=40% (95% CI 18%, 56%)) and a virological confirmed subset of symptomatic individuals (VE=60% (95% CI -38%, 89%)). CONCLUSIONS This study illustrates positive point estimates of Influenza VE across methodology and outcome for a single cohort of individuals during season 2009-10. Understanding of potential differences between approaches aids interpretation of VE results in future seasons.
منابع مشابه
Antigenic Variation of the Haemagglutinin Gene of the Influenza A (H1N1) pdm09 Virus Circulating in Shiraz, February-April 2013
Background: A new pandemic influenza A (H1N1) emerged in April 2009, causing considerable morbidity and mortality. Since mutations in the haemagglutinin (HA) may influence the antigenicity and pathogenicity of the virus, continued epidemiological and molecular characterization for the effective control of pandemic flu and developing of more appropriate vaccine is crucial. Objective: To monitor ...
متن کاملPartial Quality Control of Inactivated Split Human Influenza Vaccine 2008-9
Background and Aims: Influenza vaccination is one of the best way to prevent and control influenza worldwide. It is manufactured by WHO-licensed companies based on the WHO expertise committee annually. The aim of this study was partial quality control of the commercial human influenza vaccine 2008-9 and its matching with the circulating strains. Materials and Methods: The trivalent imported vac...
متن کاملPhylogenetic Comparison of Influenza Virus Isolates from Three Medical Centers in Tehran with the Vaccine Strains during 2008-2009
Background: Influenza virus is a major infectious pathogen of the respiratory system causing a high degree of morbidity and mortality annually. The worldwide vaccines are decided and produced annually by World Health Organization and licensed companies based on the samples collected from all over the world. The aim of this study was to determine phylogenecity and heterogenecity of the circulati...
متن کاملEffectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination
INTRODUCTION Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness. METHODS VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N...
متن کاملEffectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009-10.
OBJECTIVE To determine the effectiveness of an adjuvanted monovalent vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases. DESIGN Historical cohort study. SETTING Mandatory national reporting systems, 2 November 2009 to 31 January 2010, Denmark. PARTICIPANTS 388,069 people under 65 years of age with a diagnosis in the past five years of at least one unde...
متن کامل